Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
248 Leser
Artikel bewerten:
(0)

BC Technical Acquires MEDX

WEST JORDAN, Utah, June 8, 2013 /PRNewswire/ -- BC Technical, the nation's leading non-OEM medical imaging solutions provider, has acquired MEDX, the #2 Molecular Imaging service organization. The acquisition of MEDX follows 5 previous medical imaging acquisitions and affirms BC Technical's position as the top OEM alternative. BC Technical continues to expand their capabilities and demonstrate strength in PET, PET/CT, SPECT, SPECT/CT, NM, CT and MR solutions.

(Logo: http://photos.prnewswire.com/prnh/20120510/LA04560LOGO)

"Our acquisition of MEDX strengthens our national, multi-OEM strategy in Molecular Imaging. MEDX was the #2 player in the US, and this acquisition clearly elevates BC Technical to the only credible, nationwide Molecular Imaging alternative to the OEM's. We offer nationwide service on all Molecular Imaging systems, regardless of the OEM," said Mark Alvarez, president and CEO of BC Technical. "The few remaining local or regional Molecular Imaging players lack the credibility, scale, and capital necessary to provide the same level of uncompromised service solutions as BC Technical."

MEDX has provided new and refurbished molecular imaging equipment, service and parts since 1973. Like BC Technical, they're known for quality systems and expert service. In addition to nationwide, multi-vendor service, MEDX has provided around-the-clock technical support, clinical applications training, and accreditation assistance. Former owners, Eric Ellingson & Sean McDermott, are confident in BC Technical's position to take care of their customers and employees. Eric comments, "I believe this acquisition makes compelling sense from a customer point of view. MEDX has had a long history of terrific customer service and expertise in the molecular imaging field.This reputation, paired with BC Technical's strong presence and efficient go-to-market model, will definitely provide customers with the best choice in Molecular Imaging service."

ABOUT BC TECHNICAL

BC Technical, headquartered in West Jordan, Utah, was founded in 1995. Their comprehensive expertise in all major OEM molecular imaging systems includes the latest PET, PET/CT, SPECT and SPECT/CT technologies. Offering the same level of resources, expertise and quality that you've come to expect from large OEM's, with the added flexibility and value of smaller ISO's, they are in a category by themselves. BC Technical can provide you with the best refurbished equipment from all major OEM's, nationwide on-site service in all 50 states and personal technical/clinical support; all with uncompromised reliability, quality and value. For more information about BC Technical, please call 888-BCTECH1 (228.3241) or visit them online at www.bctechnical.com.

ABOUT MEDX

MEDX, LLC has been a leading provider of high quality new, remanufactured and refurbished molecular imaging equipment, service and parts since 1973. The company is known for quality systems and expert service, delivering over 3,000 molecular imaging systems and upgrades to facilities all over the world. MEDX continues to offer complete SPECT and PET coverage including accreditation assistance, multi-vendor field service, multi-vendor certified parts, 24/7/365 technical phone support, professional applications training and 24-hour U.S. service response.

SOURCE BC Technical

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.